Search Cancer Clinical Trials

Mass General Brigham Cancer Institute offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
22 results
  • Pancreatic Cancer, Melanoma, Lung Cancer, Liver Cancer, Kidney Cancer, Breast Cancer, Endometrial Cancer

25-587          Phase II

A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors

  • Melanoma

22-619          Phase II

A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy

  • Melanoma

23-286          Phase II

A Phase II Study of the Interleukin-6 Receptor Blocking Antibody Sarilumab in Combination with Ipilimumab, Nivolumab and Relatilimab in Patients with Unresectable Stage III or Stage IV Melanoma

  • Melanoma, Cellular Therapy

25-046          Phase III

A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)

  • Melanoma

25-125          Phase III

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma

  • Melanoma

19-499          N/A

AN OPEN LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD SPONSORED ATEZOLIZUMAB STUDY (IMBRELLA B)

  • Bladder Cancer, Lung Cancer, Melanoma, Endometrial Cancer, Head and Neck Cancer, Liver Cancer, Colorectal Cancer

24-203          Phase I

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

  • Melanoma

23-464          Phase III

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

  • Ovarian Cancer, Melanoma, Kidney Cancer

22-062          Phase II

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 ß/¿ Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies

  • Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer, Melanoma

22-405          Phase II

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors

Showing 1 - 10 of 22 results